NP2, Piramal Finish Cyclophosphamide Dev as 92% Supply is 2 Overseas Firms

For biopharma professionals tracking oncology supply chains, the Piramal-NP2 announcement is more than a development milestone: it is a direct response to a worsening US generic sterile injectable shortage. NCCN data show 100% of member centers are short at least one cancer drug, while cyclophosphamide itself is limited in the EU and Canada and 92% of US sales depend on two overseas manufacturers. Completion of the Lexington development phase next month moves a critical medicine one step closer to domestic production.

Piramal Pharma Solutions, the CDMO arm of Piramal Pharma Ltd (NSE: PPLPHARMA, BSE: 543635), and its nonprofit partner NP2 announced on September 30, 2026 that they expect to complete the drug development phase for generic cyclophosphamide in October 2026. The work is taking place at PPS's dedicated sterile injectable facility in Lexington, Kentucky. The announcement was distributed through PRNewswire and syndicated by Business Standard's press-release service, so the statements should be read as company claims rather than independently verified reporting. Still, the underlying data on US and global oncology drug shortages give the development real strategic significance. Cyclophosphamide is a widely prescribed generic sterile injectable cancer medicine used in breast cancer and retinoblastoma, a rare eye cancer affecting young children. According to NP2's Head of Manufacturing, Telly Athanasopoulos, moving to the manufacturing stage is an important step toward producing a steady US supply at stable prices.

“

NCCN data show 100% of member centers are short at least one cancer drug, while cyclophosphamide itself is limited in the EU and Canada and 92% of US sales depend on two overseas manufacturers.

The shortage environment is stark. The announcement cites a National Comprehensive Cancer Network survey conducted in late August 2026, in which 100 percent of NCCN member institutions reported a shortage of at least one anti-cancer agent, and more than 20 percent reported shortages of five or more cancer drugs. Cyclophosphamide is specifically in short supply in the EU and Canada. Q2 IQVIA sales data cited in the release show that the top two cyclophosphamide manufacturers, both overseas, account for 92 percent of US sales, and one of those suppliers serves nearly 70 percent of the US 200 mg ready-to-use solution segment. This level of concentration creates a fragile supply chain for a drug that lacks easy substitutes in many oncology protocols. By shifting development and eventual manufacturing to Lexington, PPS and NP2 aim to shorten the distance between production and US patients, reduce import dependence, and mitigate the kind of disruption that has repeatedly plagued generic sterile injectables.

Generic sterile injectables are especially prone to shortages because manufacturing is capital-intensive, margins are thin, and capacity is concentrated in a few plants. When a plant fails an inspection or faces quality issues, the entire market can tip into shortage. The fact that the top two suppliers are both overseas compounds the risk, exposing US clinics to shipping delays, trade barriers, and regulatory divergence. The Lexington expansion addresses this by adding redundant domestic capacity. The $85 million investment suggests Piramal is betting on durable demand for domestic sterile injectable manufacturing, a theme that has gained momentum since the COVID-19 pandemic exposed global supply chain vulnerabilities. NP2's nonprofit model may also help insulate production decisions from purely commercial calculus, although the partnership structure is not detailed.